Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital.
Grenouillet-Delacre M, Verdoux H, Moore N, Haramburu F, Miremont-Salamé G, Etienne G, Robinson P, Gruson D, Hilbert G, Gabinski C, Bégaud B, Molimard M. Grenouillet-Delacre M, et al. Among authors: moore n. Intensive Care Med. 2007 Dec;33(12):2150-7. doi: 10.1007/s00134-007-0787-8. Epub 2007 Jul 25. Intensive Care Med. 2007. PMID: 17653528
Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.
Laharie D, Droz-Perroteau C, Bénichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A, Moore N. Laharie D, et al. Among authors: moore n. Br J Clin Pharmacol. 2010 Mar;69(3):295-302. doi: 10.1111/j.1365-2125.2009.03588.x. Br J Clin Pharmacol. 2010. PMID: 20233201 Free PMC article.
Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.
Théophile H, Arimone Y, Miremont-Salamé G, Moore N, Fourrier-Réglat A, Haramburu F, Bégaud B. Théophile H, et al. Among authors: moore n. Drug Saf. 2010 Nov 1;33(11):1045-54. doi: 10.2165/11537780-000000000-00000. Drug Saf. 2010. PMID: 20925441
Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?
Daveluy A, Milpied B, Barbaud A, Lebrun-Vignes B, Gouraud A, Laroche ML, Ciobanu E, Bégaud B, Moore N, Miremont-Salamé G, Haramburu F; French Pharmacovigilance Centres Network and The Toxidermia Group of the French Society of Dermatology. Daveluy A, et al. Among authors: moore n. Eur J Clin Pharmacol. 2012 Jan;68(1):101-5. doi: 10.1007/s00228-011-1101-9. Epub 2011 Jul 27. Eur J Clin Pharmacol. 2012. PMID: 21792562
Is reporting rate a good predictor of risks associated with drugs?
Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Pierfitte C, et al. Among authors: moore nd. Br J Clin Pharmacol. 1999 Mar;47(3):329-31. doi: 10.1046/j.1365-2125.1999.00881.x. Br J Clin Pharmacol. 1999. PMID: 10215758 Free PMC article.
1,595 results